Group 1 - The core viewpoint of the news is that Guichuang Tongqiao (02190) has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH, marking a significant milestone in the company's globalization efforts [1] - The acquisition will be conducted in phases, allowing the company to eventually acquire all remaining shares and corresponding rights of Optimed [1] - This strategic move aims to enhance the company's presence in the European and global markets, leveraging Optimed's established R&D, manufacturing, and commercialization platform [1] Group 2 - Optimed is a German medical technology company focused on the development, production, and global sales of minimally invasive vascular and urological intervention medical devices [2] - The company has a sales and service network that covers over 70 countries and maintains close collaborations with European clinicians and academic opinion leaders [2] - Optimed's peripheral venous treatment products, including the sinus-Venous iliac vein stent, have gained significant market recognition and have been validated in clinical trials [2]
股异动 | 归创通桥(02190)盘中涨近5% 近日战略收购德国Optimed 将进一步拓展血管介入全球市场布局